

3 November 2025

ASX Announcement

## Bioxyne to Manufacture and Distribute Curaleaf Medical Inhalation Device

Bioxyne Limited (ASX: BXN) (“Bioxyne” or “the Company”), through its subsidiary Breathe Life Sciences (BLS), is pleased to advise that it has executed an exclusive import, manufacture and supply agreement with Curaleaf International for Australia.

Following import approval notification by the Therapeutic Goods Administration (TGA) on 1 October 2025, and authorization by the Office of Drug Control to import on 27 October, BLS plans to launch the Que Medical Inhalation Device (QMID) in Australia in November 2025, making it available via authorised prescribers, Special Access Scheme-Category B and pharmacies nationwide.

The QMID is the first EU Class IIa (according to the EU Medical Device Regulation (EU 2017/745)) medical device for use with medical cannabis liquid inhalants, a key differentiator from other liquid dose form inhalation products on the market.

### Key Highlights

- **Exclusive Distributor:** BLS has exclusive rights to import, manufacture (including active pharmaceutical ingredients and device filling) and distribute Curaleaf’s certified medicinal cannabis inhaler and cartridges in Australia.
- BLS has lodged an application to the TGA, who have approved importation subject to issuance of an import permit by the Office of Drug Control for Vaping Goods.
- **Nationwide Distribution from 1 November 2025:** Launch across prescribers and pharmacies to ensure patient access from day one.
- **Strong Revenue Contribution expected:** This will add a new recurring revenue stream (device + replacement cartridges) that supports Bioxyne’s FY26 guidance of revenue \$65m - \$75m and EBITDA of \$11.5m - \$13.5m.

Sam Watson, CEO, Bioxyne Limited, commented *“We are pleased to formalise our partnership with Curaleaf International, a recognised global company in the medicinal cannabis sector. Under this agreement, Bioxyne will serve as the exclusive import and manufacturing partner for the Curaleaf Que Medical Inhalation Device in Australia.”*

*This collaboration represents an important step in expanding access to regulated, medically compliant inhalation technology in Australia. The arrangement strengthens Bioxyne’s position within the medical device sector and supports our commitment to ensuring that high-quality, compliant delivery systems are available for use within the Australian therapeutic framework.”*



Juan Martinez, CEO, Curaleaf International, said *“We are excited to be partnering with Bioxyne and Breathe Life Sciences in Australia, a rapidly growing market. The launch of the QMID in Australia is part of our wider mission to develop innovative medical technologies that support healthcare professionals in the delivery of treatment. The QMID is designed as a discreet and reliable inhalation device which, together with our partner Bioxyne, can now be offered to eligible patients in Australia”.*

Approved by the Board of Bioxyne Limited for release to the ASX.

For further information, please contact:

Bioxyne Limited

Investor Relations

Email: [info@bioxyne.com](mailto:info@bioxyne.com)

Phone: +61 2 9078 8180

### **Sam Watson**

Chief Executive Officer

### **About Bioxyne and Breathe Life Sciences**

#### ***About Bioxyne Limited***

Bioxyne Limited is a licensed Australian pharmaceutical and healthcare company manufacturing and distributing novel medicines, health products and active pharmaceutical ingredients including medicinal cannabis, MDMA, and Psilocybin.

<https://bioxyne.com>

#### ***About Breathe Life Sciences (BLS)***

**Breathe Life Sciences (“BLS”)** is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances (S3, S4, S8, S9), including medicinal cannabis, Psilocybin, and MDMA.

BLS was founded in 2018 and has quickly expanded into a multi-national business focused on alternative therapeutics and investigational medicines. The company’s corporate head office is in Sydney, with operations and licensed manufacturing, warehousing, import/export, sales and distribution centres in Queensland (Australia), Nagoya (Japan), Manchester (UK), and Prague (Czechia).

The BLS business model is focused on manufacturing final dose form medicines, sales and distribution. BLS sources raw materials and API from suppliers in 5 continents and is the Australian market leading manufacturer of therapeutic goods including cannabis, MDMA, and Psilocybin.

Outside of Australia the BLS Group operates in pharmaceuticals, medical cannabis, consumer health products, and novel foods (CBD). In the UK, Europe and Japan, the Company engages in the following activities:

- a) Owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand. Internationally recognized for its cannabis-based food supplements, lifestyle



products, functional mushrooms and nootropics, and prescription medicines in Australia.

- b) Contract manufacture and wholesale of raw materials and cannabinoid extracts in Japan, UK and Europe.
- c) Contract / white label manufacture of consumer health products for brands in Japan, UK and Europe in company-owned facilities.
- d) Research and development of novel medicines.
- e) Direct sales via online and wholesale of BLS-owned consumer brands, such as Dr Watson®
  - **United Kingdom:** [drwatsoncbd.com](http://drwatsoncbd.com)
  - **UK / EU:** [breathelifesciences.com](http://breathelifesciences.com)
- f) Export and supply of medicinal cannabis products and manufacturing services to UK and European markets.

**Corporate:** [bioxyne.com](http://bioxyne.com)

**Australia:** [bls.com.au](http://bls.com.au)

**International:** [breathelifesciences.com](http://breathelifesciences.com)

## About Curaleaf International

[Curaleaf International](http://Curaleaf International) is committed to advancing research and product development in the field of medical cannabis. Powered by a strong presence at all stages of the supply chain, its unique distribution network throughout Europe, Canada and Australasia brings together pioneering research with cutting-edge cultivation, extraction, and production. Amidst a rapid growth trajectory, the emphasis on quality and expertise underpins its efforts to advance safe and responsible innovation across the cannabis sector.

Curaleaf International's network includes a clinic, pharmacy, and laboratory in the UK; cultivation and EU-GMP processing facilities in Portugal; an EU-GMP processing, quality assurance and research site in Spain; Four20 Pharma wholesaler and distributor in Germany; a Polish wholesaler and clinic; and the EU-GMP producer Northern Green Canada.

Curaleaf International is part of Curaleaf Holdings, Inc., a leading international producer and distributor of consumer cannabis products.

For all press enquiries, please contact [media@curaleafint.com](mailto:media@curaleafint.com)

## Medical Use Only

Medicinal cannabis products and devices are available in Australia only through prescription from authorized healthcare providers under the Special Access Scheme or Authorized Prescriber pathways. This announcement does not constitute medical advice.

